Infinita Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-07-2024
- Paid Up Capital ₹ 0.63 M
as on 29-07-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.88 Cr
as on 29-07-2024
- Revenue 48.23%
(FY 2023)
- Profit -53.25%
(FY 2023)
- Ebitda -38.39%
(FY 2023)
- Net Worth 46.34%
(FY 2023)
- Total Assets 125.27%
(FY 2023)
About Infinita Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.63 M.
The company currently has active open charges totaling ₹1.88 Cr.
Sonalben Desai and Adarsh Desai serve as directors at the Company.
- CIN/LLPIN
U24100GJ2015PTC084081
- Company No.
084081
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Aug 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Infinita Biotech Private Limited offer?
Infinita Biotech Private Limited offers a wide range of products and services, including Cleaning Chemicals, Odor Eliminators, Detergent Raw Material, Detergent Enzyme, Food Enzymes, Alpha Amylase, Food Additive, Textile Enzymes, Neutral Cellulase Enzyme, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Infinita Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sonalben Desai  | Director | 05-Aug-2015 | Current |
| Adarsh Desai | Director | 05-Aug-2015 | Current |
Financial Performance of Infinita Biotech.
Infinita Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 48.23% increase. The company also saw a substantial fall in profitability, with a 53.25% decrease in profit. The company's net worth Soared by an impressive increase of 46.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Infinita Biotech?
In 2023, Infinita Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 May 2023 | ₹1.38 Cr | Open |
Others Creation Date: 29 Dec 2015 | ₹5.00 M | Open |
How Many Employees Work at Infinita Biotech?
Infinita Biotech has a workforce of 48 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Infinita Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Infinita Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
